Full Text PA-95-038 NEUROSCIENCE RESEARCH OF NICOTINE AND NICOTINE ABUSE NIH GUIDE, Volume 24, Number 10, March 17, 1995 PA NUMBER: PA-95-038 P.T. 34 Keywords: Addiction Smoking Behavior Neuroscience Neurophysiology National Institute on Drug Abuse PURPOSE The purpose of this program announcement is to encourage research to examine the many aspects of nicotine abuse/addiction in in vitro or in vivo systems, in animals, and in man. The research may be based upon behavioral, neurophysiologic, neurochemical, or other methods that will seek to explain nicotine use. The overall goal is to further our understanding of the brain mechanisms that underlie addictive processes, with an eventual target of developing specific treatments for the abuse/addiction of nicotine in man. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000", a PHS-led national activity for setting priority areas. This program announcement, Neuroscience Research of Nicotine and Nicotine Abuse, is related to the priority area of tobacco. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0 or Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-783-3238). ELIGIBILITY REQUIREMENTS Applications may be submitted by domestic and foreign, for-profit and non-profit organizations, public and private, such as universities, colleges, hospitals, laboratories, units of State and local governments, and eligible agencies of the Federal government. Racial/ethnic minority individuals, women, and persons with disabilities are encouraged to apply as principal investigators. MECHANISM OF SUPPORT The mechanism available for support of this program announcement is the regular research project grant (R01). Because the nature and scope of the research proposed in response to this program announcement may vary, it is anticipated that the size of an award will vary also. RESEARCH OBJECTIVES Background Throughout history, man has maintained the ubiquitous habit of smoking, ingesting, or otherwise using tobacco products. The most common usage is inhalation of the smoke, with approximately 27 percent of the United States population lighting up cigarettes, cigars, and pipes on a regular basis. (1) Nicotine, the major pharmacologic agent in tobacco, is widely accepted to be the primary cause of this habit (2,3). In the 1964 report of the Advisory Committee of the U.S. Surgeon General on Smoking and Health, (3) the WHO Expert Committee criteria were used as the basis for viewing tobacco as a "habit" rather than an addiction. The primary reasons for the decision to define smoking, even heavy or compulsive smoking, as a habit was because of the absence of clear-cut nicotine-induced signs of physical dependence (withdrawal) in animal models, and of the belief that symptoms observed when smokers stopped using tobacco were "secondary to the deprivation of a desired object" rather than a specific nicotine-induced withdrawal effect, and of the variable duration of these cessation symptoms. Furthermore, there was the belief that the obvious tolerance that smokers showed for tobacco was of "low grade," and that a variety of interventions that appeared to help the motivated smoker in quitting this "habit." In this historic document, it was implied many times (but never actually stated) that the primary reason that people smoked tobacco was to obtain nicotine. Subsequent reports from the Surgeon General and from other prestigious national and international forums (including the Royal College of Physicians, (4) the American Psychiatric Association and the World Health Organization have left little doubt as to the addictive nature of nicotine. These were summarized in the 1988 Surgeon General's Report which incorporated more than 2500 published papers and the contributions of more than 50 scientists, and presented three major conclusions: 1. Cigarettes and other forms of tobacco are addictive, 2. Nicotine is the drug in tobacco that causes addiction, and 3. The pharmacological and behavioral processes that determine tobacco addiction are similar to those that determine addiction to drugs such as heroin and cocaine. Because of the widespread use of cigarettes and other nicotine-containing products and the recent suggestion that nicotine may be "as addictive as cocaine", the National Institute on Drug Abuse (NIDA) is seeking additional research into the many different effects of nicotine. Areas of Research Areas of research interest in this program announcement range from the in vitro biochemical and neurochemical determinations of the effects of nicotine in model systems, to in vivo studies investigating the behavioral or physiologic effects of nicotine in animals and in man. In general, these may include: o An examination of the cholinergic mechanisms involved, both peripherally and centrally, in the effects of nicotine. o Further investigations of the subtypes of nicotinic cholinergic receptors (alpha, beta, delta and gamma), and their correlation with function. o Neurobiologic and/or neurochemical techniques that utilize the underlying mechanisms of nicotine to understand the use/abuse of this substance. o Studies of individual sensitivities of animal or human systems toward the behavioral or physiologic effects of nicotine. o The development of new animal models of smoking that correlate with the human pattern of nicotine self-administration. o A comparison of the neuroanatomical sites and the neurochemical substrates in the addictive behavior of nicotine. o Effects of nicotine on cognitive performance, perception, vigilance, memory and motor skills. o Neurotoxicologic effects of nicotine in animals and/or man. o Effects of prenatal nicotine on development and social behaviors in the offspring. o Human studies on the prevalence of nicotine addiction in society and its role in fostering attitudes towards other drugs of abuse. o Autoradiographic or computer imaging studies of tobacco smoking/nicotine administration. o A comparison of behaviors (craving/withdrawal/relapse) of nicotine and other abused drugs. These areas of research are not intended to be all-inclusive, but are designed to give the applicant some direction for the types of research that NIDA is interested in exploring in its search to understand the basic mechanism(s) of nicotine abuse, as well as other abused drugs. INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS It is the policy of the NIH that women and minority groups and their subpopulations must be included in all NIH-supported biomedical and behavioral research projects involving human subjects, unless a clear and compelling rationale and justification is provided that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. This new policy results from the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43) and supersedes and strengthens the previous policies (concerning the Inclusion of Women in Study Populations, and Concerning the Inclusion of Minorities in Study Populations) which have been in effect since 1990. The new policy contains some new provisions that are substantially different from the 1990 policies. All investigators proposing research involving human subjects should read the "NIH Guidelines for Inclusion of Women and Minorities as Subjects in Clinical Research", which have been published in the Federal Register of March 28, 1994 (FR 59 14508-14513), and reprinted in the NIH GUIDE FOR GRANTS AND CONTRACTS of March 18, 1994, Volume 23, Number 11. Investigators may obtain copies from these sources or from the program staff or contact person listed below. Program staff also provide additional relevant information concerning the policy. APPLICATION PROCEDURES Applications are to be submitted on the grant application form PHS 398 (rev. 9/91) and will be accepted at the standard application deadlines as indicated in the application kit. Application kits are available at most institutional offices of sponsored research and may be obtained from the Office of Grant Information, Division of Research Grants, National Institutes of Health, Westwood Building, Room 449, Bethesda, MD 20892, telephone 301/710-0267. The title and number of the program announcement must be typed in Item 2a of face page of the application. Applicants from institutions that have a General Clinical Research Center (GCRC) funded by the NIH National Center for Research Resources may wish to identify the GCRC as a resource for conducting the proposed research. If so, a letter of agreement from either the GCRC program director or principal investigator could be included with the application. The completed original application and five legible copies of the application must be sent or delivered to: Division of Research Grants National Institutes of Health 6701 Rockledge Drive, Room 1040 - MSC 7710 Bethesda, MD 20892-7710 If overnight delivery is used, the zip code is 20817. REVIEW CONSIDERATIONS Applications that are complete and responsive to the program announcement will be evaluated for scientific and technical merit by an appropriate peer review group convened in accordance with the standard NIH peer review procedures. As part of the initial merit review, all applications will receive a written critique and undergo a process in which only those applications deemed to have the highest scientific merit, generally the top half of applications under review, will be discussed, assigned a priority score, and receive a second level review by the appropriate advisory council or board. Review Criteria: o scientific, technical, or medical significance and originality of proposed research; o appropriateness and adequacy of the experimental approach and methodology proposed to carry out the research; o qualifications and research experience of the Principal Investigator and staff, particularly, but not exclusively, in the area of proposed research; o availability of the resources necessary to perform the research; o appropriateness of the proposed budget and duration in relation to the proposed research; and o adequacy of plans to include both genders and minorities and their subgroups as appropriate for the scientific goals of the research. Plans for the recruitment and retention of subjects will also be evaluated. The initial review group will also examine the provisions for the protection of human and animals subjects, and the safety of the research environment. AWARD CRITERIA Applications will compete for available funds with all other approved applications assigned to the Institute. The following will be considered in making funding decisions: o quality of the proposed project as determined by peer review, o availability of funds, o programmatic priorities, i.e., o relevance to program goals and objectives as described in the Areas of Research Interest in the program announcement. INQUIRIES Inquiries are encouraged. The opportunity to clarify any issues or questions from potential applicants is welcome. Direct inquiries regarding programmatic issues to: David N. Johnson, Ph.D. Division of Basic Research National Institute on Drug Abuse 5600 Fishers Lane, Room 10A-19 Rockville, MD 20857 Telephone: (301) 443-6975 FAX: (301) 594-6043 Email: [email protected] Direct inquiries regarding fiscal matters to: Gary Fleming, J.D., M.A. Grants Management Branch National Institute on Drug Abuse 5600 Fishers Lane, Room 8A-54 Rockville, MD 20857 Telephone: (301) 443-6710 FAX: (301) 594-6847 Email: [email protected] AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No. 93.279. Awards are made under authorization of Section 301 of the Public Health Service Act (42 USC 241) and administered under PHS policies and Federal Regulations at Title 42 CFR 52 "Grants for Research Projects," Title 45 CFR Part 74 & 92, "Administration of Grants" and 45 CFR Part 46, "Protection of Human Subjects." This program is not subject to the inter- governmental review requirements of Executive Order 12372 or Health Systems Agency review. Sections of the Code of Federal Regulations are available in booklet form from the U.S. Government Printing Office. Grants must be administered in accordance with the PHS Grants Policy Statement, (rev. 4/94), which may be available from your office of sponsored research. The PHS strongly encourages all grant and contract recipients to provide a smoke-free workplace and promote the non-use of all tobacco products. In addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities (or in some cases, any portion of a facility) in which regular or routing education, library, day care, health care or early childhood development services are provided to children. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people. Bibiolography 1. U.S. Dept. of Health and Human Services. National Household Survey on Drug Abuse: Main Findings 1990. DHHS Publication # (ADM) 91-1788. Washington, D.C. United States Government Printing Office, 1991. 2. Nicotine Psychopharmacology (eds: S. Wonnacott, M.A.H. Russell, I.P. Stolerman) Oxford Science Publications, p. 25, 1990. 3. Reducing the Health Consequences of Smoking: Nicotine Addiction. A Report of the Surgeon General. Rockville, MD. DHHS Publication # (CDC) 88-8406. Washington, DC United States Government Printing Office, 1988. 4. Henningfield, JE, C Cohen and JD Slade. Is nicotine more addictive than cocaine? Br. J. Addiction 86: 565-569, 1991. .
Return to NIH Guide Main Index
![]() |
Office of Extramural Research (OER) |
![]() |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
![]() |
Department of Health and Human Services (HHS) |
![]() |
||||